

# High-Accuracy POCT Reagents from China: Innovations Showcased at the National Pharmaceutical Fair

NINGBO, ZHEJIANG, CHINA, February 3, 2026 /EINPresswire.com/ -- Ningbo Qinmeng Maternal and Child Products Co., Ltd., a subsidiary of Ningbo Ciliang Import and Export Co., Ltd., recently showcased its latest [China high accuracy POCT testing reagents](#) and innovative diagnostic solutions at the National Pharmaceutical Trading Fair. This new generation of testing reagents reflects China's growing strength in the field of rapid diagnostics and precision medical technology. Designed for reliability, speed, and portability, these POCT (Point-of-Care Testing) reagents represent a breakthrough in healthcare



accessibility — offering accurate results within minutes, whether used in hospitals, clinics, or home-based medical applications. As healthcare providers globally move toward real-time and decentralized testing solutions, these reagents are poised to play a critical role in improving early disease detection, maternal and infant health monitoring, and preventive medical practices.

## Industry Outlook: Rising Demand for Precision and Rapid Diagnostics

In recent years, the global healthcare market has witnessed an accelerating shift toward rapid, accurate, and portable diagnostic solutions. Point-of-Care Testing (POCT) has emerged as one of the most dynamic segments in the medical diagnostics industry, driven by advances in biotechnology, nanomaterials, and smart detection platforms. According to recent market research, the global POCT market is projected to exceed USD 60 billion by 2030, with particularly strong growth in infectious disease testing, maternal and neonatal health, and chronic disease management.

In China, the POCT sector has gained momentum through continuous investment in R&D and industrial upgrading. With the expansion of the domestic medical device manufacturing ecosystem, Chinese enterprises have moved from being low-cost producers to high-precision solution providers, capable of competing with leading international brands. The trend toward

early detection and home-based monitoring has further driven the adoption of POCT technologies in both urban and rural healthcare systems.

The COVID-19 pandemic accelerated the industry's digital transformation, highlighting the importance of reliable rapid diagnostics. Healthcare systems worldwide now demand testing tools that combine accuracy with accessibility — a shift that has opened significant opportunities for Chinese manufacturers like Ningbo Qimeng. The company's focus on high accuracy POCT testing reagents aligns precisely with this demand, integrating robust quality control, innovative biochemistry, and user-centered design.

Moreover, the integration of POCT with cloud-based data management and AI-powered interpretation tools is creating new models for preventive healthcare. As global healthcare policies increasingly emphasize decentralization, the role of rapid, affordable diagnostics will continue to grow — reinforcing the strategic importance of Chinese manufacturers in this evolving landscape.

Participation at the National Pharmaceutical Trading Fair

Ningbo Qimeng Maternal and Child Products Co., Ltd. made a strong impression at the National Pharmaceutical Trading Fair, one of the most influential platforms in China's healthcare and medical supply industry. The event gathered leading domestic and international pharmaceutical companies, medical equipment manufacturers, and healthcare solution providers to exchange ideas, display new technologies, and build business collaborations.

At its exhibition booth, Ningbo Qimeng introduced its line of POCT testing reagents designed for applications such as infectious disease detection, pregnancy testing, fertility monitoring, and maternal health diagnostics. The company demonstrated how its reagents deliver precise, consistent, and rapid results — essential features for clinical laboratories, pharmacies, and even remote medical centers. Visitors were particularly impressed by the reagents' ability to maintain accuracy across various environmental conditions and their compatibility with multiple testing platforms.

In addition to POCT products, Ningbo Qimeng highlighted its broader expertise in maternal and child health product development, showcasing its ability to merge consumer care products with diagnostic innovation. The exhibition served as an opportunity to expand business partnerships, strengthen international collaboration, and highlight China's advancements in high-accuracy medical testing technologies.

The company's participation in the fair underscores its ongoing commitment to technological innovation and global market integration. By presenting its latest diagnostic reagents and maternal care solutions, Ningbo Qimeng positioned itself as both a trusted domestic manufacturer and a forward-looking international player in healthcare technology.

Corporate Strengths and Product Applications

Founded in 2016, Ningbo Qimeng Maternal and Child Products Co., Ltd. has rapidly evolved into a modern enterprise integrating research, development, production, and sales. As a subsidiary of Ningbo Ciliang Import and Export Co., Ltd., Qimeng leverages the parent company's international trade expertise and global network to expand its presence in markets across Europe and America.

With over ten product lines and partnerships with more than 100 global collaborators, the company has earned strong recognition for product quality, innovative design, and professional

service. Its product portfolio covers maternal and child health devices, baby care items, and high-precision diagnostic tools, making it a comprehensive solutions provider in the healthcare and family wellness sectors.

The high accuracy POCT testing reagents are among the company's flagship innovations. They are developed through advanced biochemical processes and manufactured under strict quality management systems. Each reagent kit is optimized for user safety, accuracy, and reliability, with quick readout times suitable for both professional and personal use. Their applications include: Maternal and neonatal testing – such as pregnancy hormone detection and postpartum health monitoring.

Infectious disease screening – enabling early detection of key pathogens in both clinical and field settings.

Home health monitoring – providing consumers with accessible tools for daily health management.

The reagents are compatible with widely used POCT analyzers, ensuring flexibility and seamless integration into different diagnostic workflows. With a strong emphasis on usability, these products support healthcare providers in making faster clinical decisions while maintaining cost efficiency.

Ningbo Qinqing's R&D team continuously works on improving reagent stability, sensitivity, and shelf life. The company collaborates with universities and research institutions to enhance its biochemical formulations and develop next-generation testing technologies. By adopting global quality standards such as ISO and CE certifications, Qinqing ensures that its testing reagents meet international compliance requirements and deliver reliable performance worldwide.

Key customers include healthcare distributors, hospitals, and laboratories in Europe, North America, and Southeast Asia. The company's products have received widespread acclaim for their consistency and effectiveness in both clinical and retail markets. In addition, Qinqing's OEM and ODM capabilities enable customized reagent production for international partners, further solidifying its position as a trusted supplier in the medical diagnostic field.

#### Commitment to Innovation and Global Health

Ningbo Qinqing believes that innovation in diagnostics is the foundation of modern healthcare. By integrating advanced R&D with market-oriented production, the company aims to bridge the gap between professional medical environments and consumer health needs. Its strategic vision focuses on developing more precise, portable, and user-friendly testing products that improve healthcare accessibility worldwide.

As global health systems evolve toward personalized medicine and data-driven diagnostics, Ningbo Qinqing will continue to invest in the development of POCT solutions that empower early detection, support preventive care, and enhance patient outcomes. The company's efforts reflect a broader commitment to the United Nations' Sustainable Development Goal of ensuring healthy lives and promoting well-being for all.

For more information about Ningbo Qinqing Maternal and Child Products Co., Ltd., its products, and partnership opportunities, please visit the official website:

<https://www.cnciliang.com/>

Ningbo Zhengyuan Medicinal Materials Co. LTD

Ningbo Zhengyuan Medicinal Materials Co. LTD  
0086-574-63402446  
global@cnciliang.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/888852704>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.